Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor-Reference-Cited by-同舟云学术

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor

Published:2015-05-01 Issue:7 Volume:5 Page:713-722
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discovery

Author:

Piotrowska Zofia,Niederst Matthew J.,Karlovich Chris A.,Wakelee Heather A.,Neal Joel W.,Mino-Kenudson Mari,Fulton Linnea,Hata Aaron N.,Lockerman Elizabeth L.,Kalsy Anuj,Digumarthy Subba,Muzikansky Alona,Raponi Mitch,Garcia Angel R.,Mulvey Hillary E.,Parks Melissa K.,DiCecca Richard H.,Dias-Santagata Dora,Iafrate A. John,Shaw Alice T.,Allen Andrew R.,Engelman Jeffrey A.,Sequist Lecia V.

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 417 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting EGFR with molecular degraders as a promising strategy to overcome resistance to EGFR inhibitors;Future Medicinal Chemistry;2024-08-29

2. The efficacy of almonertinib and anlotinib combination therapy for advanced non‐small‐cell lung cancer patients who continued to experience cancer progression during third‐generation EGFR‐TKI treatment: a retrospective study;Thoracic Cancer;2024-07-10

3. Pancreatic ductal adenocarcinoma: the latest on diagnosis, molecular profiling, and systemic treatments;Frontiers in Oncology;2024-07-01

4. The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non‐small cell lung cancer: A meta‐analysis;The Clinical Respiratory Journal;2024-04

5. Synthetic Routes and Clinical Application of Representative Small-Molecule EGFR Inhibitors for Cancer Therapy;Molecules;2024-03-23